Physician profile
Michael Drobbin
NPI 1881981371
$3,370.63
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $67.12 · 2021: $1,695 · 2022: $383.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,411.62 | 2019-2021 | |
| Genzyme Corporation | $248.47 | 2021-2022 | |
| Intersect Ent, INC. | $201.52 | 2019-2020 | |
| Acclarent, INC | $122.38 | 2022 | |
| Abbvie INC. | $113.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2022 | |
| Glaxosmithkline, LLC. | $48.86 | 2021-2022 | |
| Optinose US, INC. | $23.07 | 2022 | |
| Pfizer INC. | $22.74 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.31 | 2021 | |
| Aerin Medical INC. | $18.10 | 2021 | |
| Merck Sharp & Dohme LLC | $15.00 | 2021 | |
| Alk-Abello, INC | $14.57 | 2021 | |
| Glenmark Therapeutics INC. | $12.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Drobbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.